{"nctId":"NCT02656069","briefTitle":"Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics","startDateStruct":{"date":"2017-03-15","type":"ACTUAL"},"conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"],"count":80,"armGroups":[{"label":"G-Pen first, then Lilly Glucagon","type":"OTHER","interventionNames":["Drug: G-Pen (glucagon injection)","Drug: Lilly Glucagon (glucagon injection [rDNA origin])"]},{"label":"Lilly Glucagon first, then G-Pen","type":"OTHER","interventionNames":["Drug: G-Pen (glucagon injection)","Drug: Lilly Glucagon (glucagon injection [rDNA origin])"]}],"interventions":[{"name":"G-Pen (glucagon injection)","otherNames":["glucagon"]},{"name":"Lilly Glucagon (glucagon injection [rDNA origin])","otherNames":["glucagon"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* diagnosed with type 1 diabetes mellitus for at least 24 months\n* usage of daily insulin treatment\n* random serum C-peptide concentration \\< 0.5 ng/mL\n\nExclusion Criteria:\n\n* pregnant or nursing\n* HbA1c \\>9.0%\n* renal insufficiency\n* hepatic synthetic insufficiency\n* aspartate or alanine aminotransferase \\> 3 times the upper limit of normal\n* hematocrit less than or equal to 30%\n* use of \\> 2.0 U/kg total insulin dose per day\n* inadequate bilateral venous access in both arms\n* congestive heart failure, New York Heart Association class II, III or IV\n* active malignancy within 5 years, except basal cell or squamous cell skin cancers\n* history of breast cancer or malignant melanoma\n* major surgical operation within 30 days\n* current seizure disorder.\n* current bleeding disorder, treatment with warfarin, or platelet count below 50,000\n* history of pheochromocytoma or disorder with increased risk of pheochromocytoma\n* history of insulinoma\n* history of glycogen storage disease.\n* positive for HIV, hepatitis C virus or active hepatitis B virus infection\n* whole blood donation of 1 pint (500 mL) within 8 weeks\n* active substance or alcohol abuse\n* administration of glucagon within 28 days\n* participation in other studies involving an investigational drug or device within 30 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hypoglycemia Rescue: Intent-to-Treat Population","description":"Number of subjects with an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]}]},{"type":"PRIMARY","title":"Hypoglycemia Rescue: Per Protocol Population","description":"Number of subjects with an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]}]},{"type":"PRIMARY","title":"Hypoglycemia Rescue: Alternate Glucose Response Definition","description":"Number of subjects with either an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL or an increase in from baseline in plasma glucose concentration of at least 20 mg/dL within 30 minutes after administration of glucagon","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Glucose Area Under the Curve (AUC)","description":"Pharmacodynamic endpoint of plasma glucose AUC from baseline to 90 minutes following administration of glucagon","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11651.4","spread":"2406.9"},{"groupId":"OG001","value":"12260.4","spread":"2134.2"}]}]}]},{"type":"SECONDARY","title":"Plasma Glucose Maximum Concentration (Cmax)","description":"Pharmacodynamic endpoint of plasma glucose Cmax from baseline to 4 hours following administration of glucagon","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"202.7","spread":"41.8"},{"groupId":"OG001","value":"193.5","spread":"42.2"}]}]}]},{"type":"SECONDARY","title":"Plasma Glucose Time to Maximum Concentration (Tmax)","description":"Pharmacodynamic endpoint of plasma glucose Tmax from baseline to 4 hours following administration of glucagon","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111.3","spread":"33.5"},{"groupId":"OG001","value":"100.4","spread":"42.7"}]}]}]},{"type":"SECONDARY","title":"Plasma Glucose Time to Concentration > 70 mg/dL","description":"Pharmacodynamic endpoint of time to achieve a plasma glucose concentration \\> 70 mg/dL following administration of glucagon","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.9","spread":"8.5"},{"groupId":"OG001","value":"14.2","spread":"4.3"}]}]}]},{"type":"SECONDARY","title":"Time to Resolution of Hypoglycemia Symptoms","description":"Time to resolution of mean autonomic, mean neuroglycopenic and mean total hypoglycemia symptom scores from baseline through 90 minutes following administration of glucagon.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":"11.5"},{"groupId":"OG001","value":"14.2","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"10.2"},{"groupId":"OG001","value":"14.3","spread":"9.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":"11.7"},{"groupId":"OG001","value":"17.0","spread":"8.9"}]}]}]},{"type":"SECONDARY","title":"Global Assessment of Hypoglycemia","description":"Time to resolution of the overall sensation of hypoglycemia following administration of glucagon","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":"10.7"},{"groupId":"OG001","value":"15.7","spread":"8.3"}]}]}]},{"type":"POST_HOC","title":"Hypoglycemia Rescue: Glucose or Symptomatic Response Definition","description":"Number of subjects with either an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL or resolution of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after administration of glucagon","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":78},"commonTop":["Nausea","Vomiting","Headache"]}}}